Genesis of Clinical Pharmacokinetic/Pharmacodynamic Concepts: E.K. Marshall,Jr.'s Role

Wagner JG . History of pharmacokinetics. Pharmacol Ther 1981; 12: 537–62.

Levy G ed. Clinical pharmacokinetics—a symposium. Washington, DC: American Pharmaceutical Association, 1974.

Bratton AC Marshall EK Jr . A new coupling component for sulfanilamide determination. J Biol Chem 1939; 128: 537–50.

Marshall EK Jr . A rapid clinical method for the estimation of urea in urine. J Biol Chem 1912–1913; 14: 283–90.

Maren TH . Eli Kennerly Marshall 1889–1966. Bull Johns Hopkins Hosp 1966; 119: 248–54.

Marshall EK Jr . The mechanism of the elimination of phenolsulfonephthalein by the kidney. A proof of secretion by the convoluted tubules. Bull Johns Hopkins Hosp 1923; 34: 1–7.

Marshall EK Jr . The comparative physiology of the kidney in relation to theories of renal secretion. Physiol Rev 1934; 14: 133–59.

Marshall EK Jr . Studies on the cardiac output of the dog. I. The cardiac output of the normal unanesthetized dog. Am J Physiol 1926; 77: 459–73.

Harvey AM . The story of chemotherapy at Johns Hopkins: Perrin H. Long, Eleanor A. Bliss, and E. Kennerly Marshall, Jr. Johns Hopkins Hosp Med J 1976; 138: 54–60.

Marshall EK Jr . Experimental basis of chemotherapy in the treatment of bacterial infections. Bull N Y Acad Med 1940; 16: 722–31.

Rowland M Sheiner LB Steimer JL eds. Variability in drug therapy—description, estimation, and control. New York: Raven Press, 1985.

Levy G . Variability in animal and human pharmacodynamic studies. In: Rowland M Sheiner LB Steimer JL eds. Variability in drug therapy—description, estimation, and control. New York: Raven Press, 1985: 125–38.

Levy G Ebling WF Forrest A . Concentration- or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther 1994; 56: 1–8.

Levy G . Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther (in press).

Peck CC . The randomized concentration-controlled clinical trial: An information-rich alternative to the randomized placebo-controlled clinical trial (abstract). Clin Pharmacol Ther 1990; 47: 148.

Sheiner LB Ludden TM . Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185–209.

Levy G . Concentration-controlled versus concentration-defined clinical trials (letter). Clin Pharmacol Ther 1993; 53: 385–7.

Peck CC . Concentration-controlled versus concentration-defined clinical trials (letter). Clin Pharmacol Ther 1993; 53: 385–7.

Boissel JP Collet JP Moleur P Haugh M . Surrogate endpoints: A basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235–44.

Levy G . Pharmacodynamic variability and individually optimized pharmacotherapy. In: Abstracts of a workshop on PK/PD and Dose—Effect Relationships in Pharmaceutical Research and Development. Institute de Recherches Internationales Servier. Paris, France, 1994.

Zhou HH Koshakji RP Silberstein DJ Wilkinson GR Wood AJJ . Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989; 320: 565–70.